These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 10549098)

  • 1. Tacrolimus toxicity due to drug interaction with mibefradil in a patient after liver transplantation.
    Ocran KW; Plauth M; Mai I; Lochs H
    Z Gastroenterol; 1999 Oct; 37(10):1025-8. PubMed ID: 10549098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serious interaction between mibefradil and tacrolimus.
    Krähenbühl S; Menafoglio A; Giostra E; Gallino A
    Transplantation; 1998 Oct; 66(8):1113-5. PubMed ID: 9808502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
    Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
    Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients.
    Jain AK; Venkataramanan R; Shapiro R; Scantlebury VP; Potdar S; Bonham CA; Ragni M; Fung JJ
    Liver Transpl; 2002 Sep; 8(9):841-5. PubMed ID: 12200788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ranolazine, tacrolimus, and diltiazem might be a hazardous combination in a transplant patient.
    Patni H; Gitman M; Hazzan A; Jhaveri KD
    Ren Fail; 2012; 34(2):251-3. PubMed ID: 22263871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diltiazem increases tacrolimus concentrations.
    Hebert MF; Lam AY
    Ann Pharmacother; 1999 Jun; 33(6):680-2. PubMed ID: 10410178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction between tacrolimus and nefazodone in a stable renal transplant recipient.
    Olyaei AJ; deMattos AM; Norman DJ; Bennett WM
    Pharmacotherapy; 1998; 18(6):1356-9. PubMed ID: 9855339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes of renal transplantation using liquid chromatographic monitoring of tacrolimus.
    Borrows R; Chusney G; Loucaidou M; James A; Stichbury J; Van Tromp J; Cairns T; Griffith M; Hakim N; McLean A; Palmer A; Papalois V; Taube D
    Ther Drug Monit; 2006 Apr; 28(2):269-73. PubMed ID: 16628143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of acute tacrolimus whole-blood elevation with phenobarbital in the pediatric liver transplant recipient.
    Quirós-Tejeira RE; Chang IF; Bristow LJ; Karpen SJ; Goss JA
    Pediatr Transplant; 2005 Dec; 9(6):792-6. PubMed ID: 16269053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus.
    McAlister VC; Peltekian KM; Malatjalian DA; Colohan S; MacDonald S; Bitter-Suermann H; MacDonald AS
    Liver Transpl; 2001 Aug; 7(8):701-8. PubMed ID: 11510015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute tacrolimus overdose and treatment with phenytoin in liver transplant recipients.
    Karasu Z; Gurakar A; Carlson J; Pennington S; Kerwin B; Wright H; Nour B; Sebastian A
    J Okla State Med Assoc; 2001 Apr; 94(4):121-3. PubMed ID: 11392178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The T- and L-type calcium channel blocker (CCB) mibefradil attenuates leg edema induced by the L-type CCB nifedipine in the spontaneously hypertensive rat: a novel differentiating assay.
    Major TC; Dhamija S; Black N; Liachenko S; Morenko B; Sobocinski G; Okerberg C; Tinholt P; Madore S; Kowala MC
    J Pharmacol Exp Ther; 2008 Jun; 325(3):723-31. PubMed ID: 18326812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement in renal function and rejection control in pediatric liver transplant recipients with the introduction of sirolimus.
    Casas-Melley AT; Falkenstein KP; Flynn LM; Ziegler VL; Dunn SP
    Pediatr Transplant; 2004 Aug; 8(4):362-6. PubMed ID: 15265163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients.
    Jain AB; Venkataramanan R; Eghtesad B; Marcos A; Ragni M; Shapiro R; Rafail AB; Fung JJ
    Liver Transpl; 2003 Sep; 9(9):954-60. PubMed ID: 12942457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
    Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients.
    Shenoy S; Hardinger KL; Crippin J; Korenblat K; Lisker-Melman M; Lowell JA; Chapman W
    Liver Transpl; 2008 Feb; 14(2):173-80. PubMed ID: 18236391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mibefradil--a T-type calcium channel blocker].
    Roguin A; Edoute Y
    Harefuah; 1999 Jan; 136(2):167-9. PubMed ID: 10914190
    [No Abstract]   [Full Text] [Related]  

  • 19. Diltiazem use in tacrolimus-treated renal transplant recipients.
    Kothari J; Nash M; Zaltzman J; Ramesh Prasad GV
    J Clin Pharm Ther; 2004 Oct; 29(5):425-30. PubMed ID: 15482385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence.
    Vivarelli M; Cucchetti A; La Barba G; Ravaioli M; Del Gaudio M; Lauro A; Grazi GL; Pinna AD
    Ann Surg; 2008 Nov; 248(5):857-62. PubMed ID: 18948815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.